Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Argenx Se ADR (NQ: ARGX )

369.83 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 30, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 100
Open 369.83
Bid (Size) 371.34 (1)
Ask (Size) 374.34 (11)
Prev. Close 369.83
Today's Range 369.83 - 369.83
52wk Range 267.35 - 407.93
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
A Bearish Sign Appears On argenx's Chart
 
Via Benzinga
Analyst Ratings for argenx
 
Via Benzinga

Performance

YTD
-1.06%
-1.06%
1 Month
+1.04%
+1.04%
3 Month
-1.59%
-1.59%
6 Month
+3.43%
+3.43%
1 Year
+17.98%
+17.98%

More News

Read More
Analyst Boosts Immunovant Price Target After Updated Pipeline Realignment
Via Benzinga
argenx Announces Annual General Meeting of Shareholders on May 2, 2023
From argenx SE
Via Globe NewsWire
argenx Announces UK MHRA Approval of VYVGART for the Treatment of Generalized Myasthenia Gravis
From argenx SE
Via Globe NewsWire
5 Analysts Have This to Say About argenx
Via Benzinga
argenx Reports Full Year 2022 Financial Results and Provides Fourth Quarter Business Update
From argenx SE
Via Globe NewsWire
Earnings Outlook For argenx
Via Benzinga
Analyst Ratings for argenx
Via Benzinga
Analyst Ratings for argenx
Via Benzinga
argenx Announces Planned Transition of Chief Operating Officer
From argenx SE
Via Globe NewsWire
argenx Appoints Steve Krognes to Board of Directors
From argenx SE
Via Globe NewsWire
argenx to Present at Upcoming Investor Conferences
From argenx SE
Via Globe NewsWire
argenx to Report Full Year 2022 Financial Results and Fourth Quarter Business Update on March 2, 2023
From argenx SE
Via Globe NewsWire
Immunovant Could Potentially Be An M&A Target, Writes Analyst
Via Benzinga
Expert Ratings for argenx
Via Benzinga
Here's What's Next For Biohaven After Its $12 Billion Pfizer Buyout, According To CEO Vlad Coric
Via Investor's Business Daily
argenx Receives Notification of PDUFA Date Extension for SC Efgartigimod
From argenx SE
Via Globe NewsWire
argenx Announces Extraordinary General Meeting of Shareholders on February 27, 2023 to Appoint Steve Krognes as Non-Executive Director
From argenx SE
Via Globe NewsWire
AT&T To Rally Over 15%? Here Are 10 Other Analyst Forecasts For Tuesday
Via Benzinga
argenx Highlights 2023 Strategic Priorities Across Immunology Pipeline
From argenx SE
Via Globe NewsWire
argenx to Present at 41st Annual J.P. Morgan Healthcare Conference
From argenx SE
Via Globe NewsWire
Alphabet To $115? Here Are 10 Other Price Target Changes For Thursday
Via Benzinga
argenx Appoints Ana Cespedes to Board of Directors
From argenx SE
Via Globe NewsWire
argenx to Present Pivotal ADVANCE Trial Data During ASH Plenary Session Highlighting VYVGART® (efgartigimod alfa-fcab) as Potential New Treatment Modality for Immune Thrombocytopenia
From argenx SE
Via Globe NewsWire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.